Company Filing History:
3 out of 576 
3 out of 88 
3 out of 1,327 
Years Active: 2019-2020
Title: Matthew Chun: Innovator in ULK1 Inhibitors
Introduction
Matthew Chun is a prominent inventor based in La Jolla, CA (US). He has made significant contributions to the field of biomedical research, particularly in the development of ULK1 inhibitors. With a total of 3 patents to his name, Chun's work is paving the way for new therapeutic methods.
Latest Patents
Chun's latest patents focus on ULK1 inhibitors and methods using the same. In certain aspects, the invention provides a method for treating a disease or condition in a subject. This method comprises co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, along with a therapeutically effective amount of an mTOR inhibitor. This innovative approach has the potential to significantly impact treatment options for various diseases.
Career Highlights
Throughout his career, Matthew Chun has worked at esteemed institutions such as the Salk Institute for Biological Studies and the Sanford Burnham Prebys Medical Discovery Institute. His research has been instrumental in advancing our understanding of cellular processes and therapeutic interventions.
Collaborations
Chun has collaborated with notable colleagues, including Reuben J. Shaw and Daniel F. Egan. These partnerships have further enriched his research and contributed to the success of his innovative projects.
Conclusion
Matthew Chun's work in ULK1 inhibitors exemplifies the impact of innovative research in the biomedical field. His contributions are not only advancing scientific knowledge but also opening new avenues for therapeutic development.